Invitae Corp.

Appointment adds business, market and partner development expertise to FYR board Addition highlights FYR’s evolution into partner of choice for drugmakers seeking deep insights into disease and treatment response MISSOULA, Mont., Jan. 09, 2025 (GLOBE NEWSWIRE) -- FYR, a visionary biotechnology company leveraging extracellular vesicles (EVs) to dynamically observe disease and treatment responses, today announced the appointment of Chris Howlett to its Independent Board of Directors. “We welcome Chris Howlett to FYR’s Board at a transformational time,” stated Chris Booth, Chief Executive Officer at FYR. “He brings a deep knowledge of the industry as an entrepreneur who has built several companies and successfully executed many deals and partnerships. As we pursue relationships with drug developers and other partners who would benefit from our disruptive approach to multiomic precision medicine, his experience will be a major asset.” “I am thrilled to join FYR as an Independent Board Member,” said Howlett. “This is an exciting time for the Company as recent data presentations at SNO and ASHG demonstrate the strength of FYR’s technology. Anticipated collaborations in 2025 will continue to prove the sensitivity and utility of FYR’s cutting-edge EV-Omics (EVO) platform. I look forward to working closely with the FYR team as the company continues to grow and demonstrate its dynamic disease insights that will transform drug development strategies from end to end.” Howlett brings over 30 years of senior and executive experience in biopharmaceutical management, with a proven track record in over 25 laboratory transactions. Most recently, he served as Chairman and CEO of Genelex, leading the company through a successful sale to Invitae. Previously, as Senior Vice President of Business Development at Unilab, he spearheaded strategy and revenue growth, driving annual revenue from $90 million to over $400 million in just four years. During his tenure, Unilab became the third-largest laboratory in the U.S., completed an IPO, and was ultimately acquired by Quest Diagnostics. Howlett also served as General Manager of one of LabCorp’s 33 divisional laboratories and spent eight years as Regional Director of a $900 million business unit. Since 2004, he has been actively involved in private market lab transactions, including the sale of Genelex, and invests in early-stage companies. Additionally, he serves on the boards of DecisionRX and Genomind and is a founding partner and board member of Market Street Healthcare Partners. About FYR FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs and better outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCsTM, to enrich extracellular vesicles from diseased cells and reveal a treasure trove of proteins and nucleic acids. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential treatment options. The unparalleled view provided by FYR’s multiomics approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyrdiagnostics.com. Media Contact:Janine McCargo6 Degreesjmccargo@6degreespr.com

环球视野，深度视角 各位亲爱的股东，大家早上好中午好晚上好。 明天，给各位股东们准备了大宝贝。 今天，纯聊天。 2024年过去了，有朋友想看我对今年行业大事的点评。 坦率的讲，我不够格。 之前在奥美一本书中，看到这样一句话： “客户终究是身在其中，他永远比我们更了解公司的内幕、市场的现状、产品的实力、成本的限制、渠道的困难，他才知道让他晚上睡不着觉的是什么？” 这一直是我用来警醒自己的一句话，所以点评就交给大佬们好了。 我只能总结自己，收获还是有的。 简单回顾下： 今年，我们大约增加了7500位股东，感谢各位关注和陪伴； 今年，我们大约完成了370篇原创文章，感谢股东们一如既往的点赞支持； 今年，我们的阅读量大约在60万左右（时刻变化，大概值），感谢每一位读者； 大概就这样了，要说成就，也算不上。 咱们新股东全年增量大概是某些大佬一周的量，但是这不重要。 重要的是，我们收获了新的朋友。 咱们全年的文章阅读量，有可能还没有一篇10w+的雄文多，但是这也不重要。 重要的是，我们陪伴股东们见证了一个个行业的历史时刻。 比如，Cue Health的破产，Invitae的破产， 比如，Bruker收购NanoString，Thermo 收购Olink，Standard BioTools合并SomaLogic； 比如，GRAIL独立分拆上市，Vizgen & Ultivue合并，华大的CycloneSeq WT02在内的国产纳米孔测序扎堆上市等等。 这些让人激动的时刻，还好，能与你分享。 这何尝不是一种收获。 另外，遇到了优秀股东们，让我知道了人与人的差距。 我曾经以为的努力到精疲力尽，在他们那里也只是日常。 他们似乎总在延续着PDCA循环，计划自己的未来，并坚决执行，时刻检视执行的结果，处理遇到的阻碍和异常。 然后，他们不知疲倦的重复着以上的过程。 并，甘之如饴。 哼，活该他们成功。 以铜为镜，可以正衣冠；以古为镜，可以知兴替；以人为镜，可以明得失。 当然，这并不是人生唯一的答案，只是对于我而言，这是一种激励。 这也是2024年，对我而言一个重要的收获。 2024年还有一个收获。 BioMarin的盐酸沙丙蝶呤片（Kuvan，商品名“科望”）退出中国后，有位小朋友的家长找到了我咨询。 其实，这款药2023年就由鲁南新时代药业仿制上市，不知道为啥，似乎宣传工作还不是很充分。 幸运的是，帮她联系到了厂家。 当然，不是所有的人都这么幸运。 另外一位可能是LCA10（Leber先天性黑蒙10型）患者家长找到我，问有没有治疗方法。 很不幸，目前没有。 Eidtas和ProQR的临床要么停要么败，让人遗憾。 2025年，我们会倾斜资源在罕见病领域。 如果国内有罕见病研究的临床试验信息、新药上市信息等，欢迎股东们后台留言或直接找我。 企业也可以，不收任何费用。 回顾自己的人生，似乎总在离梦想越来越远。 6岁的我，想要驾驶宇宙飞船，冲向塞伯坦； 16岁的我，想要把社会主义的红旗插遍世界； 26岁的我，想要升职加薪做高管迎娶白富美，走向人生巅峰； 36岁的我，想要还完车贷房贷之后，还能攒点钱养老。 按照这个节奏，我都不敢想象46岁的我还剩下什么梦想。 而如今的我，梦想又该是什么？ 不积跬步，无以至千里；不积小流，无以成江海。 或许缺的永远不是那高远的梦想，而是实实在在每天的积累。 无论要实现哪一个梦想，都要每一天每一分每一秒去锤炼。 那样，我们永远不会离梦想越来越远。 2025，与股东们共勉。 END 找小编，扫这里！ 至此，各位股东星标了么？点赞了么？转发了么？在看了么？谢谢！ 所有内容均不作为投资建议，信息均来自公开资料。 近期文章： “肠癌早筛第一股”罢免董事长 必读 | 盘点蛋白组学领域11起并购大戏，2021-2024行业风起云涌 贝瑞基因实控人51.89%股票将在淘宝拍卖 疫苗巨头BioNTech赔偿NIH 7.915亿美元 Twist CEO年基本工资仅68.5万！？ 2024年生物医药裁员/融资观察

A Silicon Valley-based startup formerly known as Ciitizen relaunched as Citizen Health on Tuesday — as well as announced a $14.5 million seed funding round led by Transformation Capital and a new partnership with the Chan Zuckerberg Initiative. The company’s efforts began in 2017, when Ciitizen launched with the aim of giving patients better access to their health records. The startup was then acquired by Invitae in 2021 through a $325 million deal with the goal of allowing patients to access genetic testing and their health records in one place. In December — two months before Invitae filed for bankruptcy — the company divested the Ciitizen platform. Invitae said that it transferred its assets to “a new entity established by the leadership team of the Ciitizen business and funded by a group of venture capital investors.” Consumer / Employer Health Executives on Digital Transformation in Healthcare Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare. By MedCity News That new entity has now officially launched, and the overarching goal has remained the same: to empower patients with access to their complete health history. Most of Ciitizen’s work focused on the oncology space, but the new startup is zeroing in on rare disease, noted Citizen Health CEO Farid Vij. “Our focus now is: how do we help patients get access to all of their information? That means their medical records, genetic genomic information, imaging data and self-reported device data so we can paint a complete picture of a patient’s health — and then really leverage AI and community to be able to drive a more personalized experience for them. And where we’re starting is in rare disease,” he explained. Vij pointed out that half a billion people worldwide are impacted by rare diseases — and 95% of these diseases don’t have a therapy. He also noted that patients and families often know more about the disease and how to navigate it than the doctor because the condition is so rare. Sponsored Post The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies. By Stephanie Baum The majority of rare disease patients are children, he added. “It’s not only a patient that’s impacted — it’s the entire family. And a lot of these are pretty severe conditions — the average patient on our platform is seen by nine different providers concurrently. So your data is kind of scattered all over the place. You’re constantly going to the neurologist and the nutritionist and the occupational therapist, and they’re not all talking to one another, so it’s really difficult to have your entire story pulled together,” Vij stated. Not only does Citizen Health pull together every patient’s individual journey, but it also allows them to share their journey with other patients on the platform. By creating a platform to discuss shared experiences, Citizen Health gives its users an opportunity to connect with others and potentially learn more about which treatments are working and which aren’t, Vij remarked. “On the other side, when you aggregate all of that information together, it is probably the richest source of data to drive research and drug development. The huge explosion we’re seeing in rare disease drug development proves that the traditional process doesn’t work well — because it’s really hard to find patients, and it’s really hard to get data around these rare populations,” he said. By stratifying the data on Citizen Health’s platform into various patient cohorts, researchers can begin to understand the natural history of certain diseases and what symptoms look like across groups of patients, Vij pointed out. As for the startup’s business model, Citizen Health does make money from sharing patient data, but users of the platform must provide explicit consent before any of their data is shared, he stated. “We talk about this all the time — that our healthcare data is sold oftentimes without our knowledge. We don’t sell data. We allow patients to be able to share their data for research purposes and be able to drive who sees their data and for what purpose. Whenever there’s any commercial use of the data, that’s when Citizen makes money — and we actually take a percent of that and share it back with the patient, as well as a percent back with our nonprofit partners if they’re involved in that condition area,” Vij explained. The nonprofit partners he mentioned are mainly organizations led by rare disease patients or their family caregivers that seek to provide support and resources for the impacted community, as well as advocate for better research. When companies are transparent with patients about the way their data is being used, patients will usually opt to share their data, Vij added. He said more than 98% of Citizen Health’s users share their data for research purposes.